Antibiotic, Bactericidal, Fluoroquinolone, Hepatic enzyme inhibitor
Fluoroquinolone antibiotic concentration dependent bactericidal.
- Contraindicated in patients with known sensitivity to this type of drug.
- Use with caution in patients with possible CNS disorders-may cause CNS stimulation and seizures.
- Use only when benefit outweighs the risk during pregnancy as safety has not been established.
- Administer orbifloxacin with caution in the presence of hepatic insufficiency/impairment.
- WARNING: Extra label use in food animals is prohibited by the FDA.
- Contraindicated in small and medium breed dogs 2 – 8 months old and large, giant breeds up to 1 year old due to the risk of articular cartilage damage.
- DO NOT EXCEED 7.5 mg/kg BODY WEIGHT PER DAY IN CATS
- Vomiting, loss of appetite, lethargy are possible side effects.
- Anaphylactic reactions, facial swelling, ataxia and seizures are also possible.
- Cartilage damage may occur-see contraindications.
- The use of fluoroquinolones in cats has been reported to adversely affect the retina. Such products should be used with caution in cats. Blindness has also been reported post-approval in cats. In some cases, blindness has been temporary.
- DO NOT EXCEED 3.4 mg/lb (7.5 mg/kg) BODY WEIGHT PER DAY IN CATS.
- Increased liver enzymes, BUN, creatinine and decreases in hematocrit have been reported in human taking fluoroquinolones. Clinical significance is unclear.
- Synergism is possible but unpredictable with aminoglycosides.
- Antacids may bind to orbifloxacin, preventing it’s absorption. Separate by 2 hours.
- Concurrent administration of fluoroquinolones may increase the action of oral anticoagulants.
- Synergism is possible but unpredictable with third generation cephalosporins.
Hepatic enzyme inhibitor
- Metabolism of other cytochrome P-450 metabolized drugs may be altered.
Penicillin / related
- Synergism is possible but unpredictable with certain penicillins.
- If given concurrently, may increase serum levels of theophylline.
- Fluoroquinolones may increase the risk of nephrotoxicity from systemic CycloSPORINE.
- Nitrofurantoin may antagonize activity of orbifloxacin.
- Sucralfate may bind to orbifloxacin, preventing it’s absorption. Separate by 2 hours.
- May inhibit theophylline metabolism and result in toxicity.
Veterinary – General
- Tablets- 5.7 mg in btls of 250 tabs, 22.7 mg in btls of 250 and 68 mg in btls of 100; Orbax® Approved for dog and cat. Oral suspension – in 20 mL bottles; ORBAX® Oral Suspension. Approved for dog and cat.